MediciNova (MNOV) News Today $1.25 +0.01 (+0.81%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$1.25 0.00 (-0.40%) As of 09/16/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNOV Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MNDSeptember 16 at 12:33 PM | markets.businessinsider.comMediciNova (NASDAQ:MNOV) Upgraded at Zacks ResearchSeptember 14 at 2:05 AM | americanbankingnews.comMediciNova provides update on SEPA, COMBAT-ALS trial enrollmentSeptember 9, 2025 | msn.comMediciNova, Inc. Announces $30 Million Standby Equity Purchase Agreement and Reports Clinical Trial Enrollment SuccessSeptember 8, 2025 | quiverquant.comQMediciNova Provides Shareholder Update on Key DevelopmentsSeptember 8, 2025 | globenewswire.comMediciNova to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | markets.businessinsider.comMediciNova to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | globenewswire.comMediciNova's (MNOV) Buy Rating Reaffirmed at D. Boral CapitalAugust 29, 2025 | marketbeat.comMediciNova, Inc. Achieves Enrollment Target for COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 for ALS TreatmentAugust 26, 2025 | quiverquant.comQMediciNova Achieves Enrollment in COMBAT-ALS Clinical TrialAugust 26, 2025 | globenewswire.comMediciNova files to sell 25M shares of common stock for holdersAugust 22, 2025 | msn.comMediciNova (NASDAQ:MNOV) Posts Earnings Results, Meets ExpectationsAugust 18, 2025 | marketbeat.comMediciNova: Q2 Earnings SnapshotAugust 14, 2025 | sfgate.comMediciNova (MNOV) to Release Quarterly Earnings on ThursdayAugust 7, 2025 | marketbeat.comMediciNova signs standby equity purchase agreement for up to $30MAugust 1, 2025 | msn.comMediciNova Secures $30 Million Equity Purchase AgreementAugust 1, 2025 | tipranks.comMediciNova, Inc. Announces Standby Equity Purchase Agreement for Up to $30 Million in Common StockJuly 31, 2025 | quiverquant.comQMediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 MillionJuly 31, 2025 | globenewswire.comMediciNova's (MNOV) Buy Rating Reiterated at D. Boral CapitalJuly 25, 2025 | marketbeat.comMediciNova, Inc.: MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical TrialsJuly 24, 2025 | finanznachrichten.deMediciNova, Inc. Reports Progress in Enrollment for Clinical Trials of MN-166 and MN-001July 24, 2025 | quiverquant.comQMediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical TrialsJuly 24, 2025 | globenewswire.comMediciNova, Inc. (MNOV) stock price, news, quote & history – Yahoo ...July 12, 2025 | au.finance.yahoo.comMediciNova, Inc. (MNOV) stock price, news, quote & history - Yahoo FinanceJune 26, 2025 | sg.finance.yahoo.comFY2025 Earnings Estimate for MediciNova Issued By B. RileyJune 18, 2025 | marketbeat.comMediciNova price target lowered to $5 from $6 at B. RileyJune 17, 2025 | finance.yahoo.comB. Riley Comments on MediciNova's Q2 Earnings (NASDAQ:MNOV)June 17, 2025 | marketbeat.comB. Riley Lowers MediciNova (NASDAQ:MNOV) Price Target to $5.00June 16, 2025 | marketbeat.comStockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV)May 20, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Now Covered by StockNews.comMay 12, 2025 | marketbeat.comMediciNova, Inc. (NASDAQ:MNOV) Sees Significant Decrease in Short InterestMay 4, 2025 | marketbeat.comStockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV)May 4, 2025 | marketbeat.comMediciNova (MNOV) Expected to Announce Earnings on ThursdayMay 3, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.comApril 26, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.comApril 17, 2025 | marketbeat.comMediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025April 14, 2025 | globenewswire.comMediciNova (NASDAQ:MNOV) Earns "Buy" Rating from D. Boral CapitalApril 11, 2025 | marketbeat.comMediciNova says first patient enrolled in EAP trial to evaluate MN-166April 9, 2025 | markets.businessinsider.comFirst Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) PatientsApril 8, 2025 | globenewswire.comMediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.comMarch 31, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.comMarch 23, 2025 | marketbeat.comMediciNova's (MNOV) "Buy" Rating Reaffirmed at D. Boral CapitalMarch 15, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Issues Earnings ResultsFebruary 20, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Releases Quarterly Earnings Results, Meets EstimatesFebruary 20, 2025 | marketbeat.comMediciNova (MNOV) Projected to Post Quarterly Earnings on ThursdayFebruary 13, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Stock Price Passes Above 200-Day Moving Average - Here's WhyJanuary 10, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Share Price Crosses Above 200 Day Moving Average - Should You Sell?January 10, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving Average - Time to Sell?January 2, 2025 | marketbeat.comMediciNova (NASDAQ:MNOV) Share Price Passes Above 200-Day Moving Average - Should You Sell?December 17, 2024 | marketbeat.comMNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial…December 9, 2024 | msn.com Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MNOV Media Mentions By Week MNOV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNOV News Sentiment▼0.980.92▲Average Medical News Sentiment MNOV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNOV Articles This Week▼41▲MNOV Articles Average Week Get the Latest News and Ratings for MNOV and Related Stocks Enter your email address to receive the latest news and analysts' ratings for MediciNova and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies FENC News Today VOR News Today EDIT News Today DBVT News Today IMMP News Today ANNX News Today VYGR News Today LYEL News Today TKNO News Today TNXP News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNOV) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediciNova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
